GO:0015658 branched-chain amino acid transmembrane transporter activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0015658 describes the molecular function that enables the transfer of branched-chain amino acids (leucine, isoleucine, valine) across a membrane.
• This activity is essential for nutrient uptake, cellular signaling, and metabolic homeostasis in organisms from bacteria to humans.
• The E. coli transporter YhjE is a recently characterized L-isoleucine and L-valine transporter that exemplifies this function.
• Transporters with this activity often use ion gradients or facilitated diffusion, and their substrate selectivity can be altered by point mutations.
• Studying GO:0015658 helps researchers understand amino acid sensing, mTOR signaling, and diseases such as cancer and metabolic disorders.
• CRISPR-based knockout, knock-in, and point-mutation models are powerful tools to dissect the physiological roles of these transporters.
Description
Branched-chain amino acids (BCAAs) — leucine, isoleucine, and valine — are essential amino acids that play critical roles in protein synthesis, energy metabolism, and cell signaling. The molecular function that mediates their movement across biological membranes is annotated as GO:0015658, branched-chain amino acid transmembrane transporter activity. This activity is fundamental for nutrient acquisition in microorganisms and for inter-organ amino acid flux in higher organisms. Recent studies have identified specific transporters, such as YhjE in Escherichia coli, that are dedicated to the uptake of L-isoleucine and L-valine, providing a model for understanding the structural and functional basis of this transport activity. Dysregulation of BCAA transport has been linked to various pathological conditions, including metabolic disorders and cancer, where altered amino acid availability can influence cell growth and survival. Therefore, characterizing the transporters that exhibit GO:0015658 activity is crucial for both basic biology and therapeutic development. This article synthesizes current knowledge on the mechanism, key genes, and research methodologies associated with this GO term, drawing on authoritative QuickGO annotations and verified PubMed literature.
branched-chain amino acid transmembrane transporter activity At A Glance
| GO ID | GO:0015658 |
|---|---|
| GO term | branched-chain amino acid transmembrane transporter activity |
| Ontology | molecular_function |
| Synonym | branched-chain aliphatic amino acid transmembrane transporter activity; branched-chain aliphatic amino acid transporter activity; leucine/valine/isoleucine permease activity; valine/tyrosine/tryptophan permease activity |
| Major function | Enables the transfer of branched-chain amino acids across a membrane |
| Substrates | L-leucine, L-isoleucine, L-valine |
| Cellular location | Integral component of membranes (plasma membrane, organellar membranes) |
| Related biological processes | Amino acid transport, nutrient sensing, protein synthesis |
What Is GO:0015658?
GO:0015658, branched-chain amino acid transmembrane transporter activity, is defined as the transfer of branched-chain amino acids from one side of a membrane to the other. Branched-chain amino acids are amino acids with a branched carbon skeleton without rings, namely leucine, isoleucine, and valine. This activity is a molecular function that can be carried out by integral membrane proteins that form channels or carriers, often using electrochemical gradients or facilitated diffusion to move substrates across lipid bilayers.
Why Is branched-chain amino acid transmembrane transporter activity Important in Cell Biology?
GO:0015658 is important because branched-chain amino acids are indispensable for protein synthesis and serve as signaling molecules that regulate key metabolic pathways, including the mTOR pathway. Transporters with this activity control the availability of BCAAs to cells, thereby influencing cell growth, proliferation, and metabolism. In microorganisms, these transporters are critical for scavenging amino acids from the environment, while in humans, they contribute to inter-organ nitrogen and carbon flux. Dysregulation of BCAA transport has been implicated in insulin resistance, obesity, and cancer, making these transporters potential therapeutic targets. Understanding their molecular mechanisms can inform drug design and metabolic engineering strategies.
• BCAA transporters are essential for the uptake of leucine, isoleucine, and valine, which are required for protein synthesis and cell growth.
• They play a key role in nutrient sensing and mTOR signaling, linking amino acid availability to cell proliferation.
• Altered BCAA transport is associated with metabolic disorders such as insulin resistance and type 2 diabetes.
• In cancer, BCAA transporters can support tumor growth by supplying essential amino acids.
• Bacterial BCAA transporters are potential targets for novel antibiotics.
• These transporters contribute to nitrogen recycling and energy metabolism in various tissues.
• Studying their substrate specificity can aid in the development of transporter-based biosensors.
• Mutations in BCAA transporters can cause rare inherited diseases, such as Hartnup disorder-like phenotypes.
• They are involved in the transport of branched-chain keto acids, which are used in the treatment of maple syrup urine disease.
• Understanding their regulation can lead to strategies for modulating amino acid levels in metabolic engineering.
What Happens During branched-chain amino acid transmembrane transporter activity?
Substrate Recognition and Binding
In simple terms: The transporter first grabs the branched-chain amino acid from one side of the membrane.
The transport cycle begins with the recognition and binding of a branched-chain amino acid (leucine, isoleucine, or valine) to a specific binding site within the transporter protein. This binding is highly selective, often discriminating between different amino acid side chains. For example, the E. coli transporter YhjE specifically recognizes L-isoleucine and L-valine, while excluding other amino acids. Structural studies of related transporters have identified critical amino acid residues that form the substrate-binding pocket, and mutations in these residues can alter substrate specificity or transport activity.
Conformational Change and Translocation
In simple terms: The transporter changes shape to move the amino acid across the membrane.
Upon substrate binding, the transporter undergoes a series of conformational changes that expose the bound amino acid to the opposite side of the membrane. This process can follow an alternating access mechanism, where the binding site alternates between outward-facing and inward-facing states. The energy for this conformational change may come from the electrochemical gradient of ions (e.g., Na+ or H+) or from ATP hydrolysis, depending on the transporter family. In the case of YhjE, transport is likely driven by the proton motive force. Mutagenesis studies on the KAAT1 transporter have shown that a single amino acid substitution (Y147F) can increase transport activity and alter substrate selectivity, highlighting the importance of specific residues in the translocation process.
Substrate Release and Reset
In simple terms: The amino acid is released inside the cell, and the transporter resets for another round.
After translocation, the branched-chain amino acid is released into the cytoplasm or the opposing compartment. The transporter then returns to its initial conformation, ready for another transport cycle. This reset step may be rate-limiting and can be regulated by cellular signals. The overall efficiency of transport is determined by the rates of binding, translocation, and release, as well as the availability of substrates and energy sources.
Regulation of Transport Activity
In simple terms: Cells can adjust how much amino acid is transported based on their needs.
The activity of branched-chain amino acid transporters is regulated at multiple levels, including gene expression, post-translational modifications, and interaction with regulatory proteins. For instance, the expression of BCAA transporters can be induced under conditions of amino acid starvation, allowing cells to scavenge scarce nutrients. Additionally, the activity of these transporters can be modulated by intracellular signaling pathways, such as the mTOR pathway, which senses amino acid levels and controls cell growth. In bacteria, the expression of BCAA transporters is often controlled by global regulators of nitrogen metabolism.
Key Genes Involved in GO:0015658 branched-chain amino acid transmembrane transporter activity
The following genes encode proteins that exhibit branched-chain amino acid transmembrane transporter activity, as supported by experimental evidence from the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| yhjE (E. coli) | L-isoleucine and L-valine transporter | Model for studying BCAA uptake in bacteria |
| KAAT1 (Manduca sexta) | K+-coupled amino acid transporter | Mutant Y147F shows altered substrate selectivity |
| LAT1 (SLC7A5) | L-type amino acid transporter 1 | Transports large neutral amino acids including BCAAs; implicated in cancer |
| LAT2 (SLC7A8) | L-type amino acid transporter 2 | Transports BCAAs and other neutral amino acids |
| PAT1 (SLC36A1) | Proton-coupled amino acid transporter | Transports small amino acids; may contribute to BCAA transport |
| BAT1 (SLC7A9) | b0,+ amino acid transporter | Transports BCAAs and cystine; mutations cause cystinuria |
| SNAT2 (SLC38A2) | Sodium-coupled neutral amino acid transporter | Transports BCAAs and other small neutral amino acids |
| SNAT4 (SLC38A4) | Sodium-coupled neutral amino acid transporter | Transports BCAAs; involved in liver metabolism |
| MCT1 (SLC16A1) | Monocarboxylate transporter | Transports branched-chain keto acids, not amino acids |
| BCAT1 | Branched-chain amino acid transaminase | Metabolizes BCAAs; not a transporter but related to BCAA metabolism |
| BCAT2 | Branched-chain amino acid transaminase | Mitochondrial isoform; metabolizes BCAAs |
| BCKDHA | Branched-chain keto acid dehydrogenase E1 alpha | Catalyzes BCAA catabolism; mutations cause maple syrup urine disease |
| SLC3A2 | 4F2 cell-surface antigen heavy chain | Chaperone for LAT1 and LAT2; essential for their transport activity |
| SLC43A1 | L-type amino acid transporter 3 | Transports BCAAs and other neutral amino acids |
| SLC43A2 | L-type amino acid transporter 4 | Transports BCAAs; involved in T-cell function |
| SLC6A15 | Orphan transporter | May transport BCAAs; expressed in brain |
| SLC7A5 | LAT1 light chain | Transports BCAAs; overexpressed in many cancers |
How Is branched-chain amino acid transmembrane transporter activity Regulated?
The activity of branched-chain amino acid transporters is regulated by multiple mechanisms. In bacteria, the expression of genes encoding BCAA transporters is often controlled by global regulators of nitrogen and carbon metabolism, such as the leucine-responsive regulatory protein (Lrp). In mammalian cells, the mTORC1 pathway senses intracellular BCAA levels and regulates protein synthesis and cell growth; conversely, BCAA transporters can influence mTORC1 activity by controlling amino acid uptake. Additionally, the localization and activity of these transporters can be modulated by post-translational modifications, such as phosphorylation and ubiquitination, and by interaction with accessory proteins like SLC3A2. Autophagy also plays a role in regulating amino acid availability by degrading cellular components, which can affect transporter expression and function.
branched-chain amino acid transmembrane transporter activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC7A5 (LAT1) | Cancer; overexpressed in tumors | Knockout in cancer cell lines; xenograft models |
| SLC7A9 (BAT1) | Cystinuria; amino acid transport defect | Knockout mouse; point mutation knock-in |
| SLC6A15 | Mood disorders; BCAA transport in brain | Knockout mouse; behavioral studies |
| BCKDHA | Maple syrup urine disease; BCAA catabolism defect | Knock-in mouse with patient mutations |
| yhjE (E. coli) | Bacterial BCAA uptake; model for transport | Knockout and overexpression in E. coli |
Cancer Metabolism
Many cancer cells exhibit increased demand for branched-chain amino acids to support rapid proliferation. Overexpression of BCAA transporters, such as LAT1 (SLC7A5), has been observed in various cancers and is associated with poor prognosis. These transporters supply BCAAs that activate mTORC1 signaling, promoting anabolic metabolism and tumor growth. Targeting BCAA transporters is therefore considered a potential therapeutic strategy.
Metabolic Disorders
Dysregulated BCAA transport and metabolism are linked to insulin resistance and type 2 diabetes. Elevated circulating BCAAs are a biomarker for these conditions, and altered expression of BCAA transporters in tissues such as muscle and liver may contribute to disease pathogenesis. Understanding how transporters regulate BCAA flux could lead to new treatments for metabolic syndrome.
Neurological Disorders
BCAAs and their transporters play roles in neurotransmitter synthesis and brain function. For example, the transporter SLC6A15 has been implicated in mood disorders and is thought to transport BCAAs in the brain. Disruption of BCAA transport may affect neuronal signaling and contribute to neurological phenotypes.
Inherited Transport Defects
Mutations in genes encoding amino acid transporters can cause rare inherited diseases. For instance, mutations in SLC7A9 (BAT1) cause cystinuria, a disorder characterized by impaired renal reabsorption of cystine and dibasic amino acids, but its role in BCAA transport is less clear. Similarly, mutations in KAAT1-like transporters could affect amino acid homeostasis, as suggested by mutagenesis studies.
From branched-chain amino acid transmembrane transporter activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of BCAA transporter loss on cell growth? | CRISPR knockout of SLC7A5 in cancer cell lines |
| How does a specific point mutation alter substrate specificity? | Point mutation knock-in of KAAT1 Y147F in insect cells |
| Can a transporter be tagged for localization studies? | Knock-in of GFP tag at the endogenous locus |
| What is the consequence of transporter overexpression? | Overexpression of yhjE in E. coli |
| Which genes are regulated by BCAA availability? | Transcriptomic analysis after knockout of BCAA transporters |
| Does a transporter mutation cause disease phenotypes? | Knock-in mouse model with patient-derived mutation |
How to Study the branched-chain amino acid transmembrane transporter activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiolabeled uptake assay | Transport activity and kinetics | Characterization of BCAA transporters |
| CRISPR knockout | Loss-of-function effects on transport | Validation of transporter genes |
| Site-directed mutagenesis | Role of specific residues in transport | Structure-function studies |
| Cryo-EM | 3D structure of transporter | Mechanistic insights |
| RNA-seq | Gene expression changes | Regulatory network analysis |
| Proteomics | Protein abundance and modifications | Post-translational regulation |
| Metabolomics | Intracellular BCAA levels | Metabolic impact of transport |
| Patch-clamp | Electrogenic transport currents | Electrophysiological characterization |
Transport Assays
Direct measurement of branched-chain amino acid transport activity can be performed using radiolabeled substrates (e.g., 3H-leucine) in cell-based or vesicle-based assays. These assays quantify uptake over time and can determine kinetic parameters such as Km and Vmax. For bacterial transporters like YhjE, uptake assays in E. coli cells or proteoliposomes are standard.
Genetic Knockout and Knockdown
CRISPR-Cas9 mediated knockout or RNA interference can be used to deplete specific transporters and assess their contribution to BCAA uptake and cellular phenotypes. For example, knockout of SLC7A5 in cancer cells reduces BCAA uptake and inhibits mTORC1 signaling.
Structural Biology
X-ray crystallography and cryo-electron microscopy can provide high-resolution structures of BCAA transporters, revealing substrate-binding sites and conformational changes. These structures guide mutagenesis studies to identify critical residues, as demonstrated for the KAAT1 transporter.
Transcriptomics and Proteomics
RNA sequencing and mass spectrometry-based proteomics can profile the expression of BCAA transporters under different conditions, such as amino acid starvation or disease states. These approaches help identify regulatory networks and potential biomarkers.
How CRISPR Can Be Used to Study GO:0015658 branched-chain amino acid transmembrane transporter activity
Knockout
CRISPR knockout of genes encoding BCAA transporters, such as SLC7A5 or yhjE, allows researchers to study the consequences of loss of transport activity on cellular metabolism, growth, and signaling. For instance, knockout of SLC7A5 in cancer cells reduces BCAA uptake and inhibits mTORC1, leading to growth arrest. In bacteria, knockout of yhjE impairs growth on isoleucine or valine as sole amino acid sources.
Point Mutation
Introducing specific point mutations via CRISPR-mediated homology-directed repair can mimic naturally occurring variants or probe structure-function relationships. For example, the Y147F mutation in KAAT1 was shown to increase transport activity and alter substrate selectivity, and a similar approach can be used to study equivalent residues in human BCAA transporters.
Knock-in
Knock-in of reporter tags (e.g., GFP, HA) or disease-associated mutations allows for real-time tracking of transporter localization and function. This approach can also be used to create cell lines expressing transporters under endogenous regulatory elements, providing more physiological relevance.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can be used to increase the expression of BCAA transporters, enabling studies of their effects on amino acid uptake, cell growth, and drug resistance. Overexpression of yhjE in E. coli enhances BCAA uptake and can be used to engineer strains for amino acid production.
How EDITGENE Supports branched-chain amino acid transmembrane transporter activity Research
Researchers studying branched-chain amino acid transmembrane transporter activity-related genes often need to determine whether a candidate gene is causally involved in amino acid transport, metabolic regulation, or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to create precise cell models that can answer these questions.
Contact EDITGENE today to design your custom CRISPR model for branched-chain amino acid transmembrane transporter activity research.
Frequently Asked Questions About branched-chain amino acid transmembrane transporter activity
What is GO:0015658?
GO:0015658 is the Gene Ontology term for branched-chain amino acid transmembrane transporter activity, which enables the transfer of leucine, isoleucine, and valine across membranes.
What genes are involved in branched-chain amino acid transmembrane transporter activity?
Genes include SLC7A5 (LAT1), SLC7A8 (LAT2), SLC43A1, SLC43A2, and bacterial yhjE, among others.
How is branched-chain amino acid transport regulated?
It is regulated by nutrient availability, mTOR signaling, and transcriptional regulators like Lrp in bacteria.
What diseases are associated with BCAA transporters?
Dysregulation is linked to cancer, insulin resistance, and neurological disorders.
What methods are used to study BCAA transporters?
Common methods include radiolabeled uptake assays, CRISPR knockout, structural biology, and transcriptomics.
Can CRISPR be used to study BCAA transporters?
Yes, CRISPR knockout, knock-in, and point mutations are powerful tools to dissect transporter function.
What is the role of YhjE in E. coli?
YhjE is an L-isoleucine and L-valine transporter that contributes to BCAA uptake.
How does the KAAT1 Y147F mutation affect transport?
The Y147F mutation increases transport activity and alters substrate selectivity.
What is the clinical relevance of BCAA transport in cancer?
Cancer cells often overexpress BCAA transporters to support growth and mTOR signaling.
How can I create a knockout of a BCAA transporter gene?
EDITGENE provides custom CRISPR knockout services for any BCAA transporter gene.
Conclusion
GO:0015658, branched-chain amino acid transmembrane transporter activity, is a fundamental molecular function that governs the uptake and distribution of leucine, isoleucine, and valine. These transporters are critical for nutrient sensing, metabolism, and cell growth, and their dysregulation contributes to cancer, metabolic disorders, and neurological conditions. Recent studies, such as the characterization of YhjE in E. coli, have advanced our understanding of the structural and functional diversity of these proteins. Continued research using CRISPR-based models and advanced biochemical assays will further elucidate their roles and therapeutic potential.
References
- 1. Foerster EG et al.. 2022. How autophagy controls the intestinal epithelial barrier.. Autophagy 18(1):86-103 PMID: 33906557
- 2. Liu Z et al.. 2003. K+ amino acid transporter KAAT1 mutant Y147F has increased transport activity and altered substrate selectivity.. J Exp Biol 206(Pt 2):245-54 PMID: 12477895
- 8. Molev SV et al.. 2025. Deciphering a missing piece of the branched-chain amino acids uptake puzzle: YhjE is an L-isoleucine and L-valine transporter in Escherichia coli K-12.. Front Microbiol 16:1727951 PMID: 41415815
